

**Important safety information  
for patients taking ZILBRYSQ® (zilucoplan)**

**PATIENT ALERT CARD**

GB-ZL-2300009

**Important Safety Information for Healthcare Professionals**

This patient has been prescribed zilucoplan, a complement component 5 (C5) inhibitor that may increase the patient's susceptibility to meningococcal infections caused by *Neisseria meningitidis*.

For more information about zilucoplan, please refer to the Summary of Product Characteristics

<https://www.medicines.org.uk/emc/search?q=zilucoplan>

**PATIENT ALERT CARD**

- Meningococcal infections may rapidly become life-threatening and can be fatal if not diagnosed and treated promptly.
- Evaluate the patient immediately. In case of suspected meningococcal infection, appropriate measures such as treatment with antibiotics and discontinuation of treatment with zilucoplan should be taken until meningococcal infection can be ruled out.
- Contact the healthcare professional who prescribed zilucoplan as soon as possible if you suspect a meningococcal infection in this patient. The prescriber is listed on this Patient Alert Card.

**Show this PATIENT ALERT CARD  
to any healthcare professional involved in your health  
care and if you go to hospital.**

Zilucoplan may increase your chances of getting a meningococcal infection, which can lead to meningitis or septicaemia. Meningitis is an infection of the linings of the brain and spinal cord. Septicaemia is an infection of the blood. These infections may quickly become life-threatening or fatal if not recognised and treated early.

**Call your doctor or seek emergency care immediately if you have any signs or symptoms of meningococcal infection.**

**Contact the listed zilucoplan prescriber as soon as possible if the patient has any signs or symptoms of meningococcal infection.**

Patient Name \_\_\_\_\_

Prescriber Name \_\_\_\_\_

CAP Patient ID UCB-ZIL-UK-

Prescriber Phone Number \_\_\_\_\_

Emergency Contact Number \_\_\_\_\_



**Important safety information  
for patients taking ZILBRYSQ® (zilucoplan)**

**PATIENT ALERT CARD**

GB-ZL-2300009

**Show this card to any treating healthcare professional.**

Keep this card with you at all times during treatment and for 2 months after your last zilucoplan dose. Your risk of meningococcal infection may continue for several weeks after your last dose of zilucoplan.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

**Carry this Patient Alert Card at all times.**

**Call your doctor or seek emergency care immediately if you have any of these signs and symptoms of meningococcal infection:**

- Headache with any of these other symptoms:  
— nausea or vomiting — stiff neck — stiff back — fever
- Fever with or without a rash
- Sensitivity of your eyes to light
- Confusion or drowsiness
- Muscle aches with flu-like symptoms

**If you have any signs or symptoms of meningococcal infection, call your doctor right away.**

**If you can't reach your doctor, seek emergency or urgent care.**

▼ This medicine is subject to additional monitoring. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

*Please report suspected side effects to the MHRA through the Yellow Card scheme, via the Yellow Card website [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard), the free Yellow Card app available in [Apple App Store](#) or [Google Play Store](#). Alternatively you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm.*

*By reporting side effects, you can help provide more information on the safety of this medicine.*

Adverse events should also be reported to UCB Pharma Ltd via UCBCares® on 0800 279 3177 (freephone) or by email [UCBCares.UK@ucb.com](mailto:UCBCares.UK@ucb.com).